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Abstract
The SARS-CoV-2 virus has spread rapidly, resulting in a global pandemic . There is a great need for an effective drug cocktail ther-
apy to combat Acute Respiratory Distress Syndrome (ARDS), a major cause of death due to COVID-19 . The two drugs examined 
are metformin, an antidiabetic medication, and rapamycin . Rapamycin is often prescribed for transplant patients as it has an 
immunosuppressive effect. The aim of the investigation was to determine the efficacy of metformin and rapamycin in treating 
COVID-19, and to examine what an effective protocol would look like . These two drugs both inhibit mTOR and can reduce the 
body’s auto-immune response, which destroys bronchial cells via cytokine storms. Both drugs have a long history of clinical use and 
have sufficient evidence of efficacy. They possess antiviral properties and downregulate inflammatory markers, making them ex-
cellent candidates for further study, both individually and in combination . Rapamycin has been shown to reverse markers of aging 
and can help repair organ damage . Importantly, metformin can help negate the toxic side effects of the potent rapamycin, while 
still preserving the positive effects of the compound . Metformin also has been shown to aid those who are at risk of developing 
ARDS due to comorbidities such as diabetes or hypertension . As such, using metformin as a preventative therapy, either alone or 
with small doses of rapamycin, may be warranted in patients at risk (Hussain et al, 2020) (Malhotra et al, 2020) .
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Introduction
The SARS-CoV-2 virus’s lethality can be largely owed to 
Acute Respiratory Distress Syndrome (ARDS), a major 
cause of death due to COVID-19. The lungs become in-
flamed and are heavily damaged as fluid from the blood 
vessels leaks into the lungs, obstructing breathing and de-
priving the organs of adequate amounts of oxygen. This 
results in high morbidity and mortality rates. The overall 
percentage of mortality in patients with ARDS was 40 
percent, making the disorder of primary importance in 
the search to reduce deaths in the patient population 
(Tzotzos et al., 2020). 
The ability to repurpose drugs is vitally important to 
combat novel pathogens and can shorten the amount of 
time and money required to develop an effective proto-
col. Novel viruses often use elements of central pathways 
that are commonly used by other viruses. Therefore, drugs 
that have been previously developed can prove efficacious, 
as they target the same pathway. Additionally, the drugs 
that are currently in use have already been proven to be 
effective and safe, which allows their immediate use until 
another, more pathogen-specific, drug can be developed. 
Furthermore, modeling the drug after an existing thera-
peutic agent can shorten the amount of time and energy 
required to develop a new agent, as portions of the previ-
ous drug can be used as a starting point. This can all add to 
an advantage that may save countless patients’ lives as they 
wait for a new drug to be developed (Husain et al, 2020). 
One of the more interesting drugs proposed as a thera-
peutic involves the use of metformin, an anti-diabetic med-
ication. This drug has been touted for its anti-inflammatory 
effects and seems to have a positive effect on the mortality 
rate of patients suffering from COVID-19, even though the 
exact mechanism of action remains contested. Possible 
theories range from its ability to act as a strong base, dis-
rupting the viral envelope, to its ability to up-regulate the 
ACE-2 enzyme, the critical binding site for the spike pro-
tein that serves as the virus’ entry point (Scheen, 2020).
Another potential drug being offered as therapy is rapa-
mycin. Rapamycin first gained recognition as an anti-re-
jection medication for transplanted organs. It suppresses 
the immune system, resulting in less inflammation, and 
has a protective effect, shielding the patient from ARDS. 
Rapamycin can ensure that even if a cure for the virus 
remains elusive, we can mitigate the negative physiological 
effects of the illness on the patients. It would therefore be 
advantageous to examine the differing protocols involv-
ing metformin and rapamycin for their efficacy in treating 
COVID-19 generally, and ARDS specifically, in vulnerable 
patient populations (Husain et al, 2020). 
Methods
Several databases (PubMed, Medscape, clinicaltrials.gov) 
were systematically reviewed for the relevant literature. 
Papers concerning the effects of metformin and rapamy-
cin were studied extensively, both in relation to COVID-
19 as well as other illnesses. 
Discussion
Metformin is a drug that is generally used in the treatment 
of type 2 diabetes as well as other metabolic conditions. 
Its widespread use and its minor side effects have led to 
it being christened the “aspirin of the 21st century.” It 
was originally introduced as an anti-influenza medication 
before being used for its effects on glucose reduction. It 
works primarily by decreasing the production of hepat-
ic glucose while simultaneously increasing the action of 
insulin on tissues, combatting a major factor of type 2 
diabetes. Metformin did not achieve widespread use in 
the United States until 1995, yet by the year 2017, it was 
the fourth most prescribed medication in the United 
States. Even though the exact mechanisms of metformin 
are unknown, there are multiple proposed mechanisms 
of action, including inhibition of the respiratory chain in 
complex I of the mitochondria and lowered production 
of cyclic AMP. Cyclic AMP is the major activating factor for 
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protein kinase A, an essential part of the second messen-
ger pathway involved in hormonal regulation. This greatly 
assists the uptake of glucose, preventing insulin resistance, 
the primary cause of type 2 diabetes. Insulin resistance is 
caused by an overproduction of insulin, which causes the 
bodily tissues to require more of the molecule to uptake 
glucose, resulting in the increasing inability of glucose to 
migrate into the resistive tissue (Sharma et al, 2020). 
The SARS-CoV-2 virus initially binds to the angioten-
sin-converting enzyme 2 (ACE2). The virus uses its spike 
protein (S) region to bind to the enzyme, forming a com-
plex that allows the virus entry into the cell. After gaining 
entry to the host, the virus will downregulate the ACE2 
receptor, leading to excessive inflammation, including car-
diovascular damage and ARDS. The inflammation is due to 
ACE2/Ang (1-7)/Mas acting within the Renin Angiotensin 
Aldosterone System (RAAS) as the anti-inflammatory 
element to counteract the ACE1–Ang II pro-inflammato-
ry arm. The inflammatory arm causes elevated systemic 
blood hypertension and inflammation. Metformin is hy-
pothesized to be able to counteract the downregulation 
of the ACE2 receptor through stimulation of the AMPK/
mTOR pathway. The AMPK/mTOR pathway is thought to 
be involved in increasing the upregulation and stability of 
ACE2, by phosphorylating ACE2 Ser680. (Malhotra et al, 
2020). Although clinical evidence in vivo is required, there 
is strong evidence that Metformin upregulates ACE2, 
from studies with human umbilical vein endothelial cells 
(HUVECs) and human embryonic kidney 293 (HEK293T) 
cells (Zhang et. al. 2018b). Additionally, phosphoryla-
tion decreases ubiquitination, extending its half-life. 
Furthermore, the phosphorylation of the ACE2 enzyme 
by a large negative phosphate group would change its 3D 
conformation and sterically hinder the binding complex 
that the virus uses for entry. In this way, metformin can 
decrease the ability of the virus to enter the host and 
reduce mortality through its upregulation of the ACE-2 
receptor (Malhotra et al, 2020). 
There is evidence that by upregulating ACE-2, 
Metformin can exhibit a protective effect on the cardio-
pulmonary system through the AMPK pathway. AMPK 
activation often leads to ACE2 conformational changes 
leading to SARS-CoV-2 having a greater difficulty binding 
to the receptor (Malhotra et. al. 2020). A study found that 
in animal models “Transgenic mice overexpressing the 
phosphomimetic ACE2 S680D exhibit less damage in pul-
monary vasculature under injurious conditions” (Zhang 
et al., 2018). Metformin has also been shown to have a 
healing effect on the pulmonary system in lipopolysaccha-
rides in animal models (Jian et al., 2013).  
The glucose-lowering effects of metformin seem to 
have a significant effect on survivability. Hyperglycemia 
has been labeled a major risk factor in various Chinese 
studies studying pulmonary illnesses. (Chen et al, 2015). A 
study of patients with diabetes and COVID-19 found that 
patients with well-controlled blood glucose levels had a 
much better prognosis and overall reductions in mortality 
(Crouse et al, 2020). As such, metformin’s proven ability to 
aid in the treatment of type 2 diabetes is important for dia-
betic patients that contract COVID-19. Another study has 
demonstrated that there is a direct correlation between 
the SARS-CoV-2 virus and diabetes, leading to speculation 
that the virus can enter the cells of the pancreatic islets 
where there is an expression of the ACE2 enzyme. This 
leads to damage to the pancreatic beta cells, which produce 
insulin, leading to transient type 2 diabetes mellitus (Yang, 
2010). This would indicate that the regulation of diabetes 
is of primary importance for the treatment of COVID-19. 
Metformin’s previously stated effects on insulin sensitivity 
would make it an ideal candidate. 
Two retrospective studies of COVID-19 patients with 
diabetes from China in early 2020 found that Metformin 
could provide benefit. In a study of diabetic patients, the 
mortality rate for patients on metformin was lower than 
the group that did not receive the drug. This was despite 
the metformin patients having higher levels of fasting glu-
cose on admission. The length of the hospital stay was 
the same between the two groups. (Luo et al. 2020). The 
SARS-CoV-2 and Diabetes Outcome study in France ini-
tially showed that patients who were given metformin 
before admissions had a lower mortality rate after seven 
days (Cariou et al, 2020).  However, multiple confounding 
factors needed to be accounted for, which once consid-
ered, rendered the findings no longer significant. 
In a retrospective analysis studying whether Metformin 
had any favorable effects 1,213 type 2 diabetic patients 
with COVID-19 in 16 hospitals in Hubei, China were 
examined. They excluded confounding variables such as 
eliminating patients with a glomerular filtration rate of 
less than 30ml/min or who had cirrhosis. Patients ex-
clusively using insulin were also eliminated. They looked 
at patients treated with metformin and other drugs 
compared to just other diabetic medications. They used 
propensity score matching to adjust for confounding 
variables and used a Cox regression model to account 
for the changes in clinical conditions throughout the pa-
tients’ stay. They discovered that the length of stay and 
the 28 days all-cause mortality rate were both unchanged, 
though metformin was associated with higher levels of 
acidosis (Lui et al, 2020). Metformin had a protective 
effect, guarding against heart failure and the body’s var-
ious inflammatory responses. Markers of heart failure, 
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inflammation, and cardiac injury were examined, and all 
were found to be lower. With these data taken together, 
according to the results of the study, Metformin exhibits a 
positive effect on cardiac failure and inflammation (Cheng 
et al., 2020). This was particularly true in severe cases but 
did not translate into an overall reduction in mortality. 
The studies’ discovery that Metformin does not influence 
mortality was contrasted by alternate findings in which 
researchers had found an improvement in patients using 
Metformin (Luo et al.2020). It is possible that since in 
the Luo study, patients on insulin were included in the 
non-Metformin group, there was a confounding variable 
that biased the results.  
The poor outcomes of diabetic patients can be ex-
plained by several factors. Patients with diabetes gener-
ally live with greater levels of overall inflammation daily, 
putting their already inflamed tissues at an increased 
risk of destruction of the bronchial epithelium by the 
body’s immune system, resulting in ARDS (Azar et al, 
2020). Elevated levels of glucose in patients with dia-
betes is an additional risk factor as high blood glucose 
levels have been shown to depress the immune system 
(Ceriello et al, 2020). These reasons make metformin a 
viable candidate for the treatment of diabetes in COVID-
19 patients, particularly as its glucose-lowering effects 
can help mitigate the negative role of diabetes (Kow et 
al, 2021). Additionally, there seem to be positive effects 
independent of the reduction of blood glucose. Various 
biochemical mechanisms are involved in Metformin’s sup-
pression of inflammatory cytokines, which would aid in 
the prevention of an overwhelming immune response on 
the part of the host (Lui et al, 2020).
Metformin’s can play a role in the reduction of inflam-
mation in patients either with or at a high risk of con-
tracting ARDS (Acute Respiratory Distress Syndrome). 
Metformin has proven to be effective at diminishing 
cytokine storms, an immune response that damages the 
body’s cells. It does this by inhibiting interleukin 1α and 
1β, important kinases for pro-inflammatory action. The 
standard measure of systemic inflammation is the neu-
trophil to lymphocyte ratio, which is used as a marker. 
Tracking these markers showed an overall reduction of 
inflammatory cytokines. In a follow-up study of nondi-
abetic patients with heart failure, it was demonstrated 
that metformin suppressed plasma cytokines (Cameron 
et al, 2016). This makes metformin a viable choice in the 
prevention of inflammation and the formation of ARDS.  
The pathway that metformin uses in its anti-inflamma-
tory effects is by the inhibition of tumor necrosis fac-
tor-α–dependent IκB (IkappaB kinase) degradation. In 
an experiment, researchers treated mouse hepatocytes 
with metformin. They found that “Metformin treatment 
for 3 hours suppressed TNFα-induced degradation of 
the NF-κB negative regulator IκB while modulating 
AMPK and mammalian target of Rapamycin signaling 
in a dose-dependent manner” (Cameron et al, 2016). 
Metformin also inhibited signaling downstream by inhib-
iting the cytokines that are normally produced and ac-
tivated, 5’ AMP-activated protein kinase (AMPK). AMPK 
is an enzyme that increases glucose uptake and is often 
thought of as a negative regulator of inflammation. In the 
same vein, IL-1β (interleukin-1-β), and IL-6 (interleukin-6) 
which are both markers of TNF-α–dependent inhibition, 
were greatly reduced (Cameron et al, 2016). 
A 30-day study examining the mortality of nursing 
home patients found that metformin was associated with 
significantly less mortality (Lally et al, 2020). Additionally, 
a retrospective analysis was made of claims made by the 
United Health group’s Clinical Discovery database. This 
study analyzed the records of enrollment of COVID-
19 patients across all 50 states, as well as the various 
pharmacy claims and laboratory reports. They found that 
when metformin was given to adults with type 2 diabe-
tes mellitus or obesity there was a marked decrease in 
mortality exclusively for women, with men receiving no 
benefit. This finding partially confirms the proposed theo-
ry that metformin would be beneficial based on its known 
effects of decreasing levels of tumor-necrosis-factor α 
(TNFα). TNFα is of particular importance as patients with 
COVID-19 have shown to have remarkably high levels of 
it in their lung tissue. Patients with diabetes also have high 
levels of TNFα, as diabetes has been shown to further el-
evate levels. Metformin also promotes the upregulation of 
anti-inflammatory cytokine, IL-10. Additionally, The study 
found that TNFα inhibitors were associated with reduced 
mortality (Bramante et al, 2020). 
This study, while interesting, has several noticeable 
flaws, including the obese and overweight patient samples 
and the lack of strength associated with retrospective 
analysis. Additionally, patients may have been prescribed 
Metformin previously, due to its prevalence, which may 
have gone unreported. It is important to stress that al-
though a helpful effect was observed, these were individ-
uals with other comorbidities such as T2DM and obesity. 
The protective effect may be much less pronounced with 
a patient group that has a lower risk factor and absence 
of these comorbidities. 
Another factor in analyzing the results of the study is 
the difference in the sensitivity required to activate mast 
cells between males and females. Mast cells are an early 
indicator for the SARS-CoV2 immune response. Females 
exhibit a far greater increase in TNFα than their male 
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counterparts. Metformin would therefore exhibit a great-
er positive effect in females, as they are naturally predis-
posed to a more severe reaction that can be inhibited 
by the drug. Women and men differed in their cytokine 
responses even though the levels of the ACE2 receptor 
were equal (Bramante et al, 2020). 
Rapamycin or Sirolimus is a potent anti-transplant re-
jection drug that can suppress and inhibit mTOR. mTOR 
is a serine/threonine-protein kinase that is composed 
of a two-part protein complex named mTORC1 and 
mTORC2. mTORC1 is the complex that is sensitive 
to rapamycin and other more common factors such as 
oxygen, glucose, and various amino acids. mTORC2 is 
insensitive to rapamycin and acts as an effector of insu-
lin/IGF-1 (Insulin-like growth factor-1). The proteins s6, 
p70S6K and 4E-BP1 are the point of control for many 
cellular functions when phosphorylated by mTORC1.
This controls protein synthesis and the cell’s self-destruc-
tion mechanism known as autophagy. mTORC2 is mostly 
required for other kinases such as Protein Kinase B. One 
of the reasons that the mTOR pathway is so vital is that it 
regulates pivotal moments in the life cycle of a cell includ-
ing metabolism, transcription, proliferation, and eventually, 
cell death. This has led mTOR, and by extension, rapamy-
cin to be often studied in the examination of aging, also 
known as cellular senescence (Husain et al, 2020). 
Rapamycin first rose to prominence when it was dis-
covered to block the immune system generally, and T cell 
proliferation specifically. Additionally, mTOR is involved in 
the cellular division cycle, playing a role in the transition 
of the G1 to the S phase. Rapamycin as an inhibitor blocks 
the cell cycle. This would suggest that mTOR can serve as 
an important chokepoint in mitigating the spread of the 
virus as it could block the proliferation of infected cells 
(Husain et al, 2020).  
In numerous studies examining the mortality of patients 
with COVID-19, it was found that that a primary factor in 
the occurrence of infectious diseases was blood Vitamin 
D concentration. In a study of elderly patients, Vitamin D 
helped reduce the inflammatory response in the upper 
respiratory epithelium and lowered the risk of developing 
intense symptoms (Grant et al , 2020). Vitamin D has also 
been shown to interact with the ACE2 enzyme, limiting 
the virus’s entry into the cell, as this serves as the entry 
point for the SARS-COV-2 virus. Evidence would suggest 
that the mechanism of action for the positive effects 
of Vitamin D is the suppression of the mTOR pathway 
through multiple mechanisms. One of these mechanisms 
involves a regulator known as “regulated in development 
and DNA damage response 1 (REDD1), a suppressor of 
mTOR activity”, which is stimulated by the 1,25(OH)2D 
form of Vitamin D (Husain et al, 2020). 
In all, it would be reasonable to suggest that the numer-
ous benefits of Vitamin D are achieved through the inhibi-
tion of mTOR and can therefore be stimulated directly by 
an mTOR inhibitory agent such as rapamycin. 
The anti-aging effects of Rapamycin can be of great use 
as well, with the drug being shown to extend the life of 
mice significantly (Harrison et al, 2009). But, important-
ly for the treatment of COVID-19, Rapamycin has been 
shown to rejuvenate damaged tissues such as damaged 
cardiac cells and increase the vitality of hematopoietic 
stem cells (Guarda et al, 2004). It may be that  as proteins 
are continuously synthesized, they acquire damage and 
various misfolding that inhibit their function and are the 
prime indicators of age-related diseases. The domain that 
is affected by rapamycin is mTORC1. Inhibiting mTORC1 
reduces protein synthesis and causes the cell to induce 
autophagy, thereby recycling the damaged components. 
COVID-19 has been proven to affect the elderly popu-
lation at an increased rate, with higher mortality being 
attributed, making rapamycin a potential anti-aging drug 
that can mitigate the negative effects of age-related vul-
nerabilities (López-Otín et al, 2013). Additionally, it might 
go some way in aiding with the reversal of organ damage 
that is a hallmark of critical cases of COVID-19. 
mTOR regulates metabolic processes that help to serve 
as signaling for anabolic (building) and catabolic (dismantling) 
processes in the cell. mTOR inhibition has been shown to 
protect against high fat-induced obesity in mice by regulating 
the breakdown of glycogen and other processes involving 
glucose. This could make rapamycin useful in mitigating the 
negative effects associated with insulin resistance and obesi-
ty in COVID-19 patients, which has been proven to result in 
negative health outcomes (Saxton et. al. 2017). 
Acute respiratory distress syndrome (ARDS) is caused 
by the breakdown of upper respiratory epithelia that 
results from a cytokine storm that destroys the body’s 
tissues. This can lead to multi-organ failure that can often 
be fatal. The various cytokines that are released are “IL-2, 
IL-7, IL-10, MCP-1 (monocyte chemoattractant protein), 
MIP1A (Macrophage Inflammatory Proteins) and TNF-α 
(Tumor Necrosis Factor-α)”. Rapamycin’s primary effect 
as an immunosuppressive drug can decrease the levels 
of the cytokines in the body, making it a useful tool for 
dealing with cytokine storms (Costela-Ruiz et al., 2020). 
Rapamycin’s targeting and inhibition of a wide variety of 
cytokines make it an ideal drug for the suppression of 
harmful immune responses, making it potentially more 
useful than the drug Tocilizumab and other monoclonal 
antibodies that merely target individual cytokines. 
Rapamycin’s inhibition of the mTOR pathway remains 
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very promising not only for its pleiotropic effects on the 
cell’s regulatory mechanisms but also for its anti-immune 
properties. It is important to mention, however, that 
rapamycin’s side effects can be rather unpredictable. This 
makes it necessary to monitor the effects of rapamycin 
in each patient and to educate them about the potential 
negative side effects. There has been a proposal to exam-
ine upstream mutations in mTORC1 signaling to deter-
mine ideal candidates for therapeutic interventions using 
rapamycin. This would help mitigate the negative side ef-
fects experienced by members of the patient population. 
T-cell senescence is prevalent in long term infections 
and cancer and is a state of T-cell dysfunction. Cytokine 
storms can play a role in inducing T-cell apoptosis and ne-
crosis, leading to overall lower T-cell counts. Patients with 
COVID-19 have been observed to have lower CD4+, 
CD8+, and total T-cell numbers which are all implicated in 
lowering the survival rate of patients with the illness. Even 
when the CD4+ and CD8+ cells are present in severely 
ill COVID-19 patients, they exhibit less function overall 
and are unable to secrete perforin, granzyme, and IFN-γ, 
all of which are cytotoxic molecules. The senescent mark-
ers PD-1 and Tim-3 are also present at higher levels. Cells 
that are senescent release certain cytokines and molecules 
that are indicative of the cell’s status and are known as 
the “senescence-associated secretory phenotype (SASP)”. 
Rapamycin, being an mTOR inhibitor, can suppress SASP 
and by extension the cytokine storm that results from 
T-cell senescence. Therefore, administration of Rapamycin 
in the early phase of the cytokine storm might prevent the 
emergence of a severe form of COVID-19 through the 
downregulation of SASP (Omarajee et al, 2020). 
Rapamycin has a history of being beneficial regarding 
respiratory infections, and has been shown to reduce the 
recovery time in H1N1 and SARS patients.  study that 
examined 38 patients with H1N1-induced pneumonia, 
reported  that Rapamycin was associated with positive 
outcomes in the overall prognosis of patients and short-
ened their time on a ventilator. It also was associated 
with significantly increased viral clearance, lower rates of 
hypoxemia, and reduced multiple organ dysfunction. Both 
H1N1 and SARS-CoV-2 activate mTOR, leading to lung 
inflammation, fever, and other intense immune reactions. 
Rapamycin may provide a significant benefit by inactivat-
ing mTOR and therefore IL-1β secretion, the mediator of 
inflammation (Wang et al., 2014).  
Rapamycin is currently undergoing phase two clinical 
trials to determine its efficacy in a 30-patient sample 
that seeks to improve clinical outcomes in COVID-19 
patients (NCT04341675). The study will last for 14 days 
with 2mg being given orally daily. The primary outcome is 
to determine the proportion of patients that do not need 
advanced respiratory support by 28 days. The secondary 
outcomes involve tracking changes in lymphocyte con-
centrations as biomarkers as well as the proportion of 
patients requiring general respiratory support. 
There have already been numerous studies done on 
the use of rapamycin and metformin in the treatment of 
a plethora of cancers and tumors, including pancreatic and 
breast cancers (Faria et al, 2019; Amin et al, 2019). These 
studies have determined the combination to be safe and 
effective, with the combination able to target slightly differ-
ent pathways than any of the two drugs alone. Rapamycin 
can cause glucose intolerance and insulin resistance if 
taken long term. These effects may be mitigated by met-
formin, due to metformin causing increased insulin sen-
sitivity in tissues. The ITP (Intervention Testing Program) 
reported that the effect of both rapamycin and metformin 
on longevity when taken together was far superior to the 
effect of each drug alone. It should be noted that in mice 
the combination of the two drugs did reduce the effective 
concentration of rapamycin in females and metformin in 
both sexes. The final concentrations were still within the 
range to be clinically useful (Strong et al, 2016). 
In a study conducted on mice, examining the effects 
of metformin on glucose, the animals were given both 
rapamycin and metformin. Interestingly, in contrast to 
studies that had been conducted previously, the research-
ers found that metformin did not inhibit mTOR and 
stopped rapamycin from inhibiting mTOR in the liver. The 
researchers theorized that metformin could alleviate the 
disfunction in gluconeogenesis that was found in other 
mTOR mutant mice (Kim et al, 2020).   
Metformin and rapamycin would seem uniquely suited 
for COVID-19 patients with obesity and diabetes. These 
patients can be aided by glucose mitigation of metformin 
but can also cycle lower doses of rapamycin for the potent 
mTOR effects. In a study of rats being given rapamycin, the 
researchers attempted to see if they could mitigate the 
increased hepatic gluconeogenesis caused by rapamycin 
administration by combining it with metformin. The female 
mice in the study exhibited significantly lower gluconeo-
genesis, thereby implying that the metformin served to 
remove the harmful side effects of rapamycin (Weiss et al, 
2018). Here, as in our previous discussion, the effect was 
sex-specific for many of the reasons outlined previously. 
In a study examining metformin and rapamycin on the 
proliferation of pancreatic cancer cell growth, the optimal 
therapeutic dosage was determined to be (20 mmol/l) 
Metformin + Rapamycin (200 ng/ml) in vivo. The study dis-
covered that the combination was vastly more effective 




In all, given the evidence that metformin reduces the 
mortality and morbidity in diabetic patients, it should 
remain a drug of primary importance in the treatment 
of COVID-19 in diabetic patients. The effects of the drug 
on insulin resistance can play an important part in re-
ducing the immunosuppression found in diabetic patients 
due to the abundance of glucose in the bloodstream. It 
should be noted that the guidelines urging concern about 
metformin inducing acidosis in patients was specifical-
ly applicable to patients already in multi-organ failure. 
Additionally, even though the prevalence of acidosis was 
higher in patients that were given metformin, it did not 
affect the mortality rate(Cheng et al, 2020). As such, the 
positive effects of metformin would make it an excellent 
candidate for further study, not only in patients with pre-
existing comorbidities but as a possible therapeutic given 
its anti-inflammatory properties. Metformin’s significant 
effects on the RAAS system can make it an important 
agent in the reduction of inflammatory cytokines that are 
the hallmarks of COVID-19.
Regarding metformin in the treatment of patients with 
COVID-19 and diabetes, it should be noted that many of 
the studies are retrospective and examine patient out-
comes using statistical analyses. They seek to determine 
the efficacy of metformin in mitigating the detrimental 
effects of diabetes on COVID-19 patients. The positive 
effects of metformin previously noted, there is a paucity 
of data of metformin being given to COVID-19 patients 
without diabetes. Many of the studies specifically look 
at the outcomes of patients who were previously given 
metformin to control diabetes before the virus and were 
then examined to determine the beneficial effects specif-
ically on patients with diabetes and COVID-19. But for 
such a widely prescribed drug such as metformin, it is 
shocking that there exists so few clinical trials for indi-
viduals without diabetes as a comorbidity. Many papers 
propose that metformin’s anti-inflammatory effects could 
be of use to the wider population to reduce the negative 
immune response, but as of the date of this paper, there 
have not been any clinical trials examining the exact out-
comes of the drug on a non-diabetic patient population. 
There may be several reasons for the lack of clinical tri-
als, among them, that even if metformin does show some 
benefit in its ability to prevent an overzealous immune 
response, other drugs currently being used or examined 
in the treatment of COVID-19 are even more effective 
through a similar mechanism. Tocilizumab, for example, 
has already been shown to help in CAR T-cell-induced 
cytokine release syndrome, which bears many similari-
ties to the cytokine storm that can occur in COVID-19. 
A common side effect of Tocilizumab, however, is an el-
evation in blood pressure, which has proven damaging 
in COVID-19 patients (Jones et al, 2010). Therefore, it 
would be efficacious to conduct a thorough study of met-
formin, given its ability to be tolerated by a wide subset of 
the population and its proposed benefits in its ability to 
downregulate the immune system. 
Additionally, many of the monoclonal antibody ther-
apies that are being examined specifically exert their 
effects on one target, while metformin has been shown 
to operate across many different pathways. Metformin 
lowers inflammation and oxidative stress, all the while 
enhancing the immune system of patients.
Rapamycin can be a dangerous compound that must be 
handled with caution due to its ability to act as a potent 
inhibitor of mTOR. While mTOR inhibition can be ben-
eficial in the reduction of inflammation, it is important 
not to inhibit the pathway completely. A study examining 
the effects of rapamycin on elderly patients discovered 
that total inhibition of mTOR stops the function of T cells 
and leads to complete immunosuppression. While some 
suppression of the immune system is favorable due to 
its effect on cytokine storms, the body’s natural defens-
es must remain viable. As such, the dose of rapamycin 
must be carefully monitored to be safe and effective. In 
that same study, they determined that the most effective 
dose at promoting a healthy immune response in elderly 
patients was the lowest dose of rapamycin followed by 
a flu shot (Mannik et al., 2014). This has a great deal of 
significance as of early 2021, due to the availability of the 
mRNA COVID-19 vaccine currently seeing widespread 
use. The use of rapamycin followed by a vaccine should 
possibly be explored as a method of enhancing immunity 
in vulnerable patient populations. This could maximize 
the effectiveness of a protocol involving not only the cur-
rently available vaccine, but also carries implications for 
other protocols involving vaccinations. 
The combination of rapamycin and metformin used in 
pancreatic cancer has been proven to be safe and effec-
tive. The dose used was the optimal dose to lower the 
expression of mTOR in pancreatic cells, and it stands to 
reason that this dosage would work in other cases where 
mTOR should be partially inhibited, such as in COVID-19. 
Rapamycin inhibits mTOR directly, while metformin does 
it through the AMPK pathway (Zheng et al, 2020).
The dose of rapamycin administered must be carefully 
controlled to avoid negative side effects. Metformin can 
temper some of these effects, which can include insu-
lin resistance and glucose intolerance, through its ability 
to promote insulin sensitivity. Rather than administering 
the two drugs as a cocktail, risk can be assessed by the 
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administration of each drug separately. This would allow 
a thorough examination of the differing effects while still 
allowing metformin to counter the deleterious side ef-
fects of rapamycin. 
An important point in discussions concerning the 
treatment of viruses is the health of the host. It has been 
demonstrated that immunocompromised patients and 
those with significant comorbidities fare far worse than 
patients without these complications. Metformin has the 
dual role of not only directly combatting the virus, but 
also reinforcing the immune system of the host. The abil-
ity to reduce comorbidities (e.g.: diabetes) should not be 
treated flippantly. A major factor in the morbidity rate 
in the United States has been a large proportion of the 
population with high blood pressure and obesity (Azar 
et al, 2020). These conditions have been proven to have 
significant negative effects. If metformin can provide a 
mechanism to reduce these additional comorbidities, the 
patient’s health outcomes could be vastly improved. 
Taking metformin to prevent an extremely negative 
reaction to COVID-19 should be considered. Being that 
metformin is a mild mitochondrial toxin that blocks 
mTOR, it would be a useful preventative drug. mTOR 
inhibitors have been shown to block viral action and ex-
press innate antiviral gene expression. In previous studies, 
mTOR inhibitors were effective against other coronavi-
ruses. Prescribing metformin to vulnerable patient pop-
ulations as a preventative drug may grant the benefits of 
mTOR inhibition without rapamycin’s toxic side effects 
(Benedetti et al, 2020).  
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